Literature DB >> 22868510

Favorable response of heavily treated Wilms' tumor to paclitaxel and carboplatin.

Saeko Ozaki1, Nagio Takigawa, Eiki Ichihara, Katsuyuki Hotta, Isao Oze, Etsuko Kurimoto, Soichiro Fushimi, Tetsuya Ogino, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura.   

Abstract

BACKGROUND: Heavily treated Wilms' tumor responding to the combination of paclitaxel and carboplatin has not yet been reported. CASE REPORT: A 17-year-old man presented with hematuria. He received a diagnosis of Wilms' tumor with multiple lung metastases and was treated with preoperative chemotherapy including vincristine, dactinomycin, and doxorubicin, a right nephrectomy, and adjuvant chemotherapy, followed by pulmonary metastasectomy. During the next 8 years, he suffered from 4 relapses and has been treated with multiple anticancer agents including high-dose chemotherapy with autologous peripheral blood stem cell transplantation. Finally, the disease progressed due to peritoneal and pleural metastases. With opioid administration for left shoulder pain due to pleural metastasis, he received combination chemotherapy with carboplatin (area under the curve = 4) and paclitaxel (175 mg/m(2)) on day 1. After 2 cycles, he achieved a partial response with mild toxicity. He received 7 cycles of the chemotherapy and the time to progression was 200 days.
CONCLUSION: In a refractory case after intensive treatments, we succeeded to control the disease for a while.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22868510     DOI: 10.1159/000338532

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  1 in total

1.  Carboplatin-based Nanomedicine to Enhance the Anticancer Effect in SK-NEP-1 WilmsꞌTumor Cells.

Authors:  Ming Ming; Zhao-Long Ma; Yong-Tao Xu; Feng-Yin Sun; Xin-Hai Cui
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.